摘要
Colorectal cancer is a heterogeneous disease.Activating mutations in genes like K-RAS,BRAF,and PI3K contribute towards a poor prognosis of the disease.In this report,we present the case of re-treatment of a 58-year old patient of metastatic colorectal cancer with a combination of anti-EGFR and chemotherapy.The patient who harbored wild-type RAS gene was administered several lines of therapies including anti-EGFR antibodies.In spite of the different regimens involved,a significant progression of disease involving metastasis to the lungs and the brain was observed.On re-treatment with cetuximab and chemotherapy,the quality of life improved and the tumor biomarkers decreased.Re-treatment with anti-EGFR antibodies and chemotherapeutic agents can be an option for patients showing adverse prognosis after several lines of therapies.
